Astrocytoma surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Surgery is the mainstay of treatment for specific type of astrocytoma such as [[glioblastoma multiforme]]. The feasibility of [[surgery]] depends on the stage of astrocytoma at [[diagnosis]]. | Surgery is the mainstay of treatment for specific type of astrocytoma such as [[glioblastoma multiforme]]. The feasibility of [[surgery]] depends on the stage of astrocytoma at [[diagnosis]]. | ||
==Surgery== | |||
* A NIH Consensus Conference report in 1999 recommends that any SEGA that is growing or causing symptoms should be surgically removed. [Tumor]]s are also removed in cases where a patient is suffering from a high [[seizure]] burden. If a [[tumor]] is rapidly growing or causing symptoms of [[hydrocephalus]], deferring [[surgery]] may lead to [[vision]] loss, need for [[ventricular shunt]], and ultimately [[death]]. Total removal of the [[tumor]] is curative. | * A NIH Consensus Conference report in 1999 recommends that any SEGA that is growing or causing symptoms should be surgically removed. [Tumor]]s are also removed in cases where a patient is suffering from a high [[seizure]] burden. If a [[tumor]] is rapidly growing or causing symptoms of [[hydrocephalus]], deferring [[surgery]] may lead to [[vision]] loss, need for [[ventricular shunt]], and ultimately [[death]]. Total removal of the [[tumor]] is curative. | ||
* [[Surgery]] to remove [[intraventricular tumor]]s also carries risks of complications or death. Potential complications include transient [[memory]] impairment, [[hemiparesis]], [[infection]], chronic ventriculoperitoneal shunt placement, [[stroke]], and [[death]]. | * [[Surgery]] to remove [[intraventricular tumor]]s also carries risks of complications or death. Potential complications include transient [[memory]] impairment, [[hemiparesis]], [[infection]], chronic ventriculoperitoneal shunt placement, [[stroke]], and [[death]]. | ||
Revision as of 15:44, 24 August 2015
|
Astrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Study |
|
Astrocytoma surgery On the Web |
|
American Roentgen Ray Society Images of Astrocytoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Surgery is the mainstay of treatment for specific type of astrocytoma such as glioblastoma multiforme. The feasibility of surgery depends on the stage of astrocytoma at diagnosis.
Surgery
- A NIH Consensus Conference report in 1999 recommends that any SEGA that is growing or causing symptoms should be surgically removed. [Tumor]]s are also removed in cases where a patient is suffering from a high seizure burden. If a tumor is rapidly growing or causing symptoms of hydrocephalus, deferring surgery may lead to vision loss, need for ventricular shunt, and ultimately death. Total removal of the tumor is curative.
- Surgery to remove intraventricular tumors also carries risks of complications or death. Potential complications include transient memory impairment, hemiparesis, infection, chronic ventriculoperitoneal shunt placement, stroke, and death.
- Surgery is needed for most primary brain tumors. Some tumors may be completely removed. In cases where the tumor cannot be removed, surgery may help reduce pressure and relieve symptoms.
- Surgical removal remains the mainstay of treatment for glioblastoma multiforme, provided that unacceptable neurologic injury can be avoided. The extremely infiltrative nature of this tumor makes complete surgical removal impossible.
- Chemotherapy or radiation therapy may be used for certain tumors.
- Surgery is used to diagnose and treat childhood astrocytoma. If cancer cells remain after surgery, further treatment depends on:
- Even if the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that remain. [1][2]
References
- ↑ "Supependymal Giant Cell Tumor (SGCT) or Subependymal Giant Cell Astrocytoma (SEGA)" (PDF). Tuberous Sclerosis Alliance. June 2006. Retrieved 9 September 2014.
- ↑ Campen, Cynthia J.; Porter, Brenda E. (August 2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Current Treatment Options in Neurology. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.